Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial. Elizabeth M. Berry-Kravis, Mark D. Harnett, Scott A. Reines, Melody A. Reese, Lauren E. Ethridge, Abigail H. Outterson, Claire Michalak, Jeremiah Furman and Mark E. Gurney. 2021-04-29 Nature Medicine Crossref DOI NCT 03569631
Design and Synthesis of Selective Phosphodiesterase 4D (PDE4D) Allosteric Inhibitors for the Treatment of Fragile X Syndrome and Other Brain Disorders. Gurney ME, Nugent RA, Mo X, Sindac JA, Hagen TJ, Fox D 3rd, O’Donnell JM, Zhang C, Xu Y, Zhang HT, Groppi VE, Bailie M, White RD, Romero DL, Vellekoop AS, Walker JR, Surman MD, Zhu L, Campbell RF. J Med Chem. 2019 Apr 23. doi: 10.1021/acs.jmedchem.9b00193. PMID: 31013090
Genetic Association of Phosphodiesterases With Human Cognitive Performance. Gurney ME. Front Mol Neurosci. 2019; 12:22. Published online 2019 Feb 8. doi: 10.3389/fnmol.2019.00022. PMID: 30800055
Memory enhancing effects of BPN14770, an allosteric inhibitor of phosphodiesterase-4D, in wild-type and humanized mice. Zhang C, Xu Y, Chowdhary A, Fox D 3rd, Gurney ME, Zhang HT, Auerbach BD, Salvi RJ, Yang M, Li G, O’Donnell JM. Neuropsychopharmacology. 2018 Oct; 43(11):2299-2309. doi: 10.1038/s41386-018-0178-6. Epub 2018 Aug 14. PMID: 30131563
The Use of Facebook Advertising to Recruit Healthy Elderly People for a Clinical Trial: Baseline Metrics. Cowie JM, Gurney ME. JMIR Res Protoc. 2018 Jan 24;7(1):e20. doi: 10.2196/resprot.7918. PMID: 29367186
Multiple Behavior Phenotypes of the Fragile-X Syndrome Mouse Model Respond to Chronic Inhibition of Phosphodiesterase-4D (PDE4D). Gurney ME, Cogram P, Deacon RM, Rex C, Tranfaglia M. Scientific Reports. 2017 Nov;7(14653).PMID: 29116166 doi: 10.1038/s41598-017-15028-x
Therapeutic benefits of phosphodiesterase 4B inhibition after traumatic brain injury. Wilson NM, Gurney ME, Dietrich WD, Atkins CM. PLoS One. 2017 May 19;12(5):e0178013. doi: 10.1371/journal.pone.0178013. eCollection 2017. PMID: 28542295
Chronic Cognitive Dysfunction after Traumatic Brain Injury is Improved with a Phosphodiesterase 4B Inhibitor. Titus DJ, Wilson NM, Freund JE, Carballosa MM, Sikah KE, Furones C, Dietrich WD, Gurney ME, Atkins CM. J Neurosci. 2016 Jul 6;36(27):7095-108. doi: 10.1523/JNEUROSCI.3212-15.2016. PMID: 27383587
Phosphodiesterase-4 (PDE4) molecular pharmacology and Alzheimer’s disease. Gurney ME, D’Amato EC, Burgin AB. Neurotherapeutics. 2015 Jan;12(1):49-56. doi: 10.1007/s13311-014-0309-7. PMID: 25371167
Discovery of triazines as selective PDE4B versus PDE4D inhibitors. Hagen TJ, Mo X, Burgin AB, Fox D 3rd, Zhang Z, Gurney ME. Bioorg Med Chem Lett. 2014 Aug 15;24(16):4031-4. doi: 10.1016/j.bmcl.2014.06.002. Epub 2014 Jun 12. PMID: 24998378
Structural basis for the design of selective phosphodiesterase 4B inhibitors. Fox D 3rd, Burgin AB, Gurney ME. Cell Signal. 2014 Mar;26(3):657-63. doi: 10.1016/j.cellsig.2013.12.003. Epub 2013 Dec 19. PMID: 24361374
Small molecule allosteric modulators of phosphodiesterase 4. Gurney ME, Burgin AB, Magnusson OT, Stewart LJ. Handb Exp Pharmacol. 2011;(204):167-92. doi: 10.1007/978-3-642-17969-3_7. Review. PMID: 21695640
Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Burgin AB, Magnusson OT, Singh J, Witte P, Staker BL, Bjornsson JM, Thorsteinsdottir M, Hrafnsdottir S, Hagen T, Kiselyov AS, Stewart LJ, Gurney ME. Nat Biotechnol. 2010 Jan;28(1):63-70. doi: 10.1038/nbt.1598. Epub 2009 Dec 27. PMID: 20037581
Tumor Necrosis Factor (TNF) Blocking Agents Reduce Risk for Alzheimer’s Disease in Patients with Rheumatoid Arthritis and Psoriasis (Preprint, 2019 Sept 27) Mengshi Zhou, David Kaelber, Rong Xu, Mark Gurney, doi: https://doi.org/10.1101/19007666 https://www.medrxiv.org/content/10.1101/19007666v1
